HSIC

Business profile & competitive position

Henry Schein, Inc. operates in the Healthcare sector, specifically the Medical – Distribution industry. The company runs a health-care solutions network built around three reportable segments. Its Global Distribution and Value-Added Services segment supplies dental and medical merchandise, equipment, repair services, pharmaceuticals, vaccines, and value-added services. Global Specialty Products manufactures and markets dental implants, biomaterials, endodontic, orthodontic, and orthopedic products. Global Technology develops and distributes practice management software, e-services, and other technology-enabled products for health-care providers. This three-segment structure ties together physical distribution, proprietary manufacturing, and software services.

The company’s scale is significant: 38 distribution centers covering more than 5.4 million square feet, 17 manufacturing facilities totaling about 0.6 million square feet, an average of roughly 150,000 cartons shipped daily, and 127 equipment sales and service centers worldwide. As of its most recent 10-K, the stocked catalog exceeded 300,000 products, and its technology segment served approximately 95,000 active practices and 324,000 consumers.

The financial footprint lines up with a business that converts scale into steady if not extraordinary returns. The latest figures show a net margin of 3.0% and return on equity of 12.4%. A 3.0% net margin is typical of a high-volume distributor that competes on breadth of catalogue, logistics efficiency, and customer relationships rather than pricing power alone. The 12.4% ROE, on the other hand, indicates the company is generating a respectable return on shareholder capital once its asset base and leverage are taken into account. Together, these numbers suggest a competitive moat built on distribution density and customer reach rather than on premium margins.

Financial posture

Henry Schein currently carries a market capitalization of $10.2 billion and trades at a price-to-earnings ratio of 25.9. That P/E sits well above what a no-growth distributor might command, so the market is pricing in continued earnings durability or modest growth from its software and specialty products mix. The net margin of 3.0% and ROE of 12.4% reinforce the profile of a capital-efficient distribution business rather than a high-gross-margin pharmaceutical or device maker.

The stock’s beta is 0.81, meaning it has historically moved less than the broad market. That fits a defensive, non-discretionary health-care distributor whose underlying demand comes from routine office visits, equipment replacement cycles, and recurring consumables. At the current snapshot, the price is $89.52, the RSI reads 61.6, and the 50-day exponential moving average is $84.89. Price sitting above the 50-day EMA with an RSI near 60 points to recent strength without pushing deep into overbought territory, but it does not by itself imply a directional outlook.

Strategic priorities & outlook

Henry Schein’s most recent 10-K filing lays out a clear operational agenda. The company’s growth framework is the BOLD+1 plan, which targets high growth by building complementary software, specialty, and services businesses. Operationally, it is working to “One Distribution” to improve customer experience while driving efficiency and growth. It is also using the “One Schein” concept to broaden and deepen customer relationships across its dental, medical, and technology platforms. Finally, the company lists digital transformation as a priority both for its own operations and for the customers it serves.

The infrastructure data supports that strategy. With 38 distribution centers and 17 manufacturing facilities, Henry Schein has the physical footprint to bundle products, services, and software into multi-year customer relationships. The technology segment’s active user base of roughly 95,000 practices and 324,000 consumers gives it a recurring touchpoint with providers, which is consistent with the goal of deepening relationships and expanding digitally. In short, the stated priorities are not abstract; they are backed by a real logistics network and an installed software base.

Macro & geopolitical exposure

As a Medical – Distribution company with a global footprint, Henry Schein faces exposures common to the industry. The first is health-care regulation. Changes in FDA rules, medical-device oversight, drug distribution licensing, or reimbursement policies can alter product sourcing, pricing, and margins. Because the company serves office-based dental and medical practitioners, any shifts in insurance reimbursement, Medicare or Medicaid payment rates, or dental benefit coverage can influence the purchasing decisions of its end customers.

Trade policy and currency are also relevant. Global distribution networks move inventory across borders, so tariffs or customs changes can affect cost of goods sourced from international manufacturers. With manufacturing and distribution centers worldwide, foreign exchange movements can impact reported revenue and margins. Supply-chain disruption risk is inherent: the company ships roughly 150,000 cartons daily, so fuel, freight, and logistics capacity costs matter directly. Finally, commodity input costs for packaging, plastics, and metals used in devices and equipment can feed through to pricing and gross margins. These are sector-level dynamics rather than company-specific predictions, but they are the macro channels that matter for this type of business.

Recent developments

Over the past two weeks, Henry Schein has drawn attention from equity commentary focused on style factors. On August 6, 2026, Zacks published “HSIC or SAUHY: Which Is the Better Value Stock Right Now?” followed on August 10, 2026, by both “Should Value Investors Buy Henry Schein (HSIC) Stock?” and “Here’s Why Henry Schein (HSIC) is a Strong Momentum Stock.” On August 14, 2026, Zacks ran “Henry Schein (HSIC) is a Top-Ranked Growth Stock: Should You Buy?” These headlines are notable because they place the same ticker in value, momentum, and growth discussions within a single week. That pattern reflects an equity being screened by multiple factor-based strategies, but it does not by itself confirm any operational catalyst.

There is no material earnings-related guidance change or acquisition news embedded in these headlines. Traders should treat them as sentiment and style-rotation signals rather than as events that alter the fundamental business. The cluster of articles around August 10–14 also coincided with the stock trading near $89.52, above its 50-day EMA and with RSI around 61.6, which often accompanies the kind of technical attention these articles describe.

Earnings behavior & post-earnings drift

Henry Schein’s recent earnings record is one of reliable beats but negative after-hours drift. Over the last eight reported quarters, the company has beaten the market’s real expectation in six of them, for a 75% beat rate, with an average earnings surprise of 2.9%. Despite that consistency, the average 5-day price move in the five trading days after earnings has been -2.05%, classified as a downward drift.

The last four quarters show the tension clearly. The most recent report, on August 4, 2026, delivered EPS of $1.27 versus an estimate of $1.24, a 2.4% beat; the stock rose 0.54% the next day and eked out a 0.08% gain over the following five days. The prior quarter, May 5, 2026, was a much larger beat: actual EPS of $1.32 versus $1.20, a 10% surprise, yet the stock fell 2.6% the next day and 6.75% over the next five days. Before that, the February 24, 2026, report beat by 3.1% ($1.34 vs $1.30) and still sold off 1.73% the next day and 3.77% over five days. The November 4, 2025, quarter was the exception: EPS of $1.38 versus $1.27, an 8.7% beat, drove a 0.56% next-day gain and a 2.25% five-day gain.

The pattern suggests the market has often priced in optimistic expectations ahead of the release. Even when the unofficial consensus is exceeded, the size of the beat or the tone of guidance can lead to near-term selling pressure. The next scheduled report is November 3, 2026, before the open, with the current consensus EPS estimate at $1.35. Traders watching this name should weigh the strong 75% beat rate against the historically negative post-earnings drift rather than assuming a beat will automatically produce upward momentum.

For a deeper dive into how institutional analysts currently weight these factors, it is worth reviewing the full institutional verdict on HSIC.